TOKYO, Japan, December 16, 2025 – RealizeEdge Partners Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Yoshitsugu Shitaka, Ph.D.; "RealizeEdge Partners") is pleased to announce the initiation of activities aimed at the commercialization of E6795, a novel therapeutic drug candidate for atopic dermatitis. As part of this effort, RealizeEdge Partners has entered into an agreement with Eisai Co., Ltd. (Location: Bunkyo-ku, Tokyo; hereinafter, "Eisai") to receive E6795 and related information for research purposes, allows for its use in value-enhancement activities.

E6795 is a novel, orally administered therapeutic candidate originated by Eisai. It holds the potential to demonstrate efficacy against atopic dermatitis and other immune diseases by modulating multiple immune responses. The compound is expected to become a First-in-Class treatment with a new mechanism of action for atopic dermatitis.

RealizeEdge Partners aims to leverage its research and business development capabilities to maximize the value of this compound through further evaluation and development.

Looking ahead, RealizeEdge Partners will explore diverse commercialization opportunities, including the potential establishment of a new company, with the goal of delivering E6795 as a groundbreaking new therapy to patients.

About Eisai

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Website: https://www.eisai.com/index.html

About RealizeEdge Partners

RealizeEdge Partners is a Tokyo-based startup studio established in April 2025. We support innovators with breakthrough ideas to accelerate the creation of drug discovery startups transforming health and brightening lives by integrating scientific excellence with strategic and operational support.
Website: https://realizeedge.com/en/